Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results

Alzheimer's and Dementia

Volumn 5, Issue 2, 2009, Pages 93-104

[No Author Info available]

Author keywords

Alzheimer's disease; Clinical trials; Prevention

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; COGNITION DISORDERS; ENCEPHALITIS; FEMALE; HUMANS; MALE; NAPROXEN; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PLACEBOS; PYRAZOLES; RESEARCH DESIGN; SULFONAMIDES; TIME; TREATMENT OUTCOME;

EID: 62849112328     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2008.09.004     Document Type: Article

References (46)

1. Alzheimer A. About a peculiar disease of the cerebral cortex [translated by L. Jarvik and H. Greenson]. Alzheimer Dis Assoc Disord 1 (1987) 3-8
2. Anderson R.N. Deaths: leading causes for 2000. Natl Vital Stat Rep 50 (2002) 1-88
3. Brookmeyer R., Johnson E., Ziegler-Graham K., and Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3 (2007) 186-191
4. Brookmeyer R., Gray S., and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88 (1998) 1337-1342
5. Martin B.K., Meinert C.L., and Breitner J.C.S. ADAPT Research Group. Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clin Trials 23 (2002) 93-99
6. Tschanz J.T., Corcoran C., Skoog I., Khachaturian A.S., Herrick K.M., Hayden K.L.M., et al. Dementia: the leading predictor of death after age 85. The Cache County Study. Neurology 62 (2004) 1156-1162
7. Tschanz J.T., Welsh-Bohmer K.A., Lyketsos C.G., Corcoran C., Green R.C., Hayden K., et al. Conversion to dementia from mild cognitive disorder: the Cache County Study. Neurology 67 (2006) 229-234
8. Meinert C., and Brietner J.C.S. Chronic disease long-term drug prevention trial: lessons from the Alzheimer's Disease Anti-Inflammatory Trial (ADAPT). Alzheimers Dement 4 Suppl. (2008) S7-14
9. Silverman J.M., Smith C.J., Marin D.B., Mohs R.C., and Propper C.B. Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry 60 (2003) 190-197
10. Silverman J.M., Li G., Zaccario M.L., Smith C.J., Schmeidler J., Mohs R.C., et al. Patterns of risk in first-degree relatives of patients with Alzheimer's disease. Arch Gen Psychiatry 52 (1995) 317-319
11. Prince M., Cullen M., and Mann A. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC Elderly Hypertension Trial. Neurology 44 (1994) 97-104
12. van Duijn C.M., Clayton D., Chandra V., Fratiglioni L., Graves A.B., Heyman A., et al. Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20 Suppl. 2 (1991) S13-S20
13. Theis K.A., Helmick C.G., and Hootman J.M. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. J Womens Health 16 (2007) 441-453
14. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68 (2007) 1800-1808
15. ADAPT Research Group. Cardiovascular and cerebrovascular results from the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.
16. Stoops N. Educational attainment in the United States: 2003. Current Popul Rep 2004; US Census Bureau, pp. 1-10. Available at: http://www.census.gov/prod/2004pubs/p20-550.pdf.
17. Katzman R., and Kawas C. The epidemiology of dementia and Alzheimer disease. In: Terry R.D., Katzman R., and Bick K.L. (Eds). Alzheimer disease (1994), Raven Press, Ltd, New York 105-122
18. Masferrer J.L., Seibert K., Zweifel B., and Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. Proc Natl Acad Sci USA 89 (1992) 3917-3921
19. Solomon S.D., McMurray J.J.V., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
20. Nissen S.E. The wrong way to stop a clinical trial. PLoS Clin Trials 1 (2006) e35. doi:10.1371/journal.pctr.0010035
21. Breitner J.C.S., Martin B.K., and Meinert C.L. The suspension of treatments in ADAPT: Concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin Trials 1 (2006) e41. doi:10.1371/journal.pctr.0010041
22. Salpeter S.R., Gregor P., Ormiston T.M., Whitlock R., Raina P., Thabane L., et al. Meta-Analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med 119 (2006) 552-559
23. Breitner J.C.S., Evans D., Lyketsos C., Martin B., and Meinert C. ADAPT trial data. Am J Med 120 (2007) e3
24. Salpeter S.R., and Topol E.J. Letter: the reply. Am J Med 120 (2007) e5
25. Alpert J.S. Editor's note re policy requiring written permission from individuals or groups generating data used in a meta-analysis. Am J Med 120 (2006) e7
26. Solomon S.D., Wittes J., Finn P.V., Fowler R., Viner J., Bertagnolli M.M., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The Cross Trial Safety Analysis. Circulation 117 (2008) 2104-2113
27. ADAPT Steering Committee. Statement for the FDA Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee (read by C. Lyketsos); 18 February 2005.
28. Teng E.L., and Chui H.C. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48 (1987) 314-318
29. Wechsler D. Wechsler Adult Intelligence Scale-Revised, manual (1981), Psychological Corp., New York
30. Wilson B., Cockburn J., Baddeley A., and Hiorns R. The development and validation of a test battery for detecting and monitoring everyday memory problems. J Clin Exp Neuropsychol 11 (1989) 855-870
31. Brandt J. The Hopkins Verbal Learning Test: development of a new verbal memory test with six equivalent forms. Clin Neuropsychol 5 (1991) 125-142
32. Benedict R.H., Schrectlen D., Groninger L., Dobrashi M., and Shpritz B. Revision of the Brief Visuospatial Memory Tests: studies of normal performance, reliability and validity. Psychol Assess 8 (1996) 145-153
33. Squire L.R., Wetzel C.D., and Slater P.C. Memory complaint after electroconvulsive therapy: assessment with a new self-rating instrument. Biol Psychiatry 14 (1979) 791-801
34. Yesavage J.A., Brink T.L., Rose T.L., and Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17 (1983) 37-49
35. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 (1989) 1159-1165
36. Reitan R.M. Trail Making Test: manual for administration and scoring (1986), Reitan Neuropsychological Laboratory, Tucson
37. Wechsler D. Wechsler Memory Scale-Revised manual (1987), Psychological Corp., San Antonio
38. Benton A. Revised Visual Retention Test. 4th ed (1974), Psychological Corp., New York
39. Benton A., and Hamsher K. Multilingual Aphasia Examination (1988), University of Iowa Press, Iowa City
40. Smith A. Symbol Digit Modalities Test-manual (1982), Western Psychological Services, Los Angeles
41. Zachary R.A. Shipley Institute of Living Scale-revised manual (1991), Western Psychological Services, Los Angeles
42. Clark C.M., and Ewbank D.C. Performance of the Dementia Severity Rating Scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 10 (1986) 31-39
43. Silverman J.M., Breitner J.C.S., Mohs R.C., and Davis K.L. Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry 143 (1986) 1279-1282
44. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., and Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994) 2308-2314
45. Barehenn E, Lurie P, Wolfe SN. Letter to HHS Secretary Tommy Thompson that raises ethical concerns about the "Alzheimer's Disease Anti-Inflammatory Prevention Trial" (ADAPT) (HRG Publication #1637). 4 Sept 2002. www.citzen.org/publication/release.cfm?ID=7195
46. Barbehenn E, Lurie P, Wolfe SN. Letter to NIH Director that continues to raise ethical concerns about the "Alzheimer's Disease Anti-Inflammatory Prevention Trial" (ADAPT) (HRG Publication #1663) 13 April 2003. (accessed 27 March 2008).